CalciMedica, Inc. (NASDAQ:CALC) Insider Acquires $17,850.00 in Stock

CalciMedica, Inc. (NASDAQ:CALC) insider Eric W. Roberts acquired 5,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were bought at an average price of $3.57 per share, for a total transaction of $17,850.00. Following the completion of the purchase, the insider now owns 46,894 shares in the company, valued at approximately $167,411.58. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

CalciMedica Stock Down 0.2 %

Shares of CALC stock opened at $4.20 on Thursday. CalciMedica, Inc. has a 12-month low of $1.75 and a 12-month high of $8.38. The company has a 50 day moving average of $4.39 and a 200-day moving average of $4.66. The firm has a market cap of $45.15 million, a P/E ratio of -1.95 and a beta of 1.28.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CALC shares. Oppenheimer upped their price objective on shares of CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 10th. Singular Research upgraded CalciMedica to a “moderate buy” rating in a report on Friday, June 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of CalciMedica in a research report on Tuesday, August 13th.

Institutional Trading of CalciMedica

A hedge fund recently raised its stake in CalciMedica stock. BML Capital Management LLC grew its holdings in shares of CalciMedica, Inc. (NASDAQ:CALC) by 10.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 160,424 shares of the company’s stock after purchasing an additional 15,000 shares during the quarter. CalciMedica comprises approximately 0.4% of BML Capital Management LLC’s portfolio, making the stock its 27th biggest holding. BML Capital Management LLC owned 1.49% of CalciMedica worth $667,000 at the end of the most recent quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.